{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-297169","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.182936+00:00","generated_at":"2026-06-07T11:34:20.364986+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veru prices public offering of 45.8M shares at $0.72, net proceeds ~$35.2M for enobosarm trial","bullets":["Entered underwriting agreement for 45,833,333 shares at $0.72/share; gross proceeds ~$33M.","Underwriters' option for 6,874,999 additional shares exercised in full on Dec 15.","Net proceeds expected ~$35.2M after discounts and expenses.","Proceeds primarily fund Phase 2b trial of enobosarm for muscle preservation in obese elderly on GLP-1 agonists.","Offering expected to close Dec 18, 2023; Raymond James and Oppenheimer lead."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-297169","json":"https://secwatch.observer/filing/0001193125-23-297169.json","markdown":"https://secwatch.observer/filing/0001193125-23-297169.md","text":"https://secwatch.observer/filing/0001193125-23-297169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312523297169/0001193125-23-297169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312523297169/d584595d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:34:20.364986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"801604798da00ff76c41cec3af55d6017fd13cbe","claim":"VERU INC. entered into Underwriting Agreement with Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. valued at Offering of 45,833,333 shares of common stock at $0.72 per share, net proceeds approximately $35.2 m (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, Veru Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Raymond James & Associates, Inc. and Oppenheimer & Co. Inc., as representatives of the underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale (the “Offering”) of 45,833,333 shares of the Company’s common stock, par value $0.01 per share, at a public offering price of $0.72 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/863894/000119312523297169/0001193125-23-297169-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Raymond James & Associates, Inc. and Oppenheimer & Co. Inc."},{"label":"Value","value":"Offering of 45,833,333 shares of common stock at $0.72 per share, net proceeds approximately $35.2 m"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}